PROF. DROR HARATS, M.D.

Professor Dror Harats founded ImmuneWalk Therapeutics based on more than 30 years of industry experience, with strong background in management of early- to mid-stage biotechnology companies, driving growth from inception to pipeline development and all the way through Phase 3 clinical trials & pre-commercialization. In addition to his multidisciplinary expertise in research, regulatory and clinical development, as CEO, he took a company through NASDAQ listing and raised over $300 million dollars from institutional funds and strategic partners. Prof. Harats is also an experienced consultant specializing in biotechnology and pharmaceutical healthcare companies.

Prof. Harats currently serves on the board of directors of Art Healthcare Ltd, and as a part time chair of the R&D division at the Chaim Sheba Medical Center at Tel Hashomer and as chair of its Institute Review Board. Prof. Harats is also a Professor of Medicine in the Departments of Internal Medicine and Biochemistry at the Sackler Faculty of Medicine of Tel-Aviv University, Israel.

Prof. Harats received a doctor of medicine degree from the Hadassah Medical School, the Hebrew University, Jerusalem, Israel. Following an internship at Sheba Medical Center and a residency in medicine at the Hadassah Medical Center in Jerusalem, he conducted a fellowship in pulmonary medicine and research in molecular genetics at The University of California in San Francisco (UCSF). He was then a visiting scientist at Syntex Discovery Research in Palo Alto, Calif. for three years.

Prof. Harats has published more than 200 peer-reviewed research papers and chapters in books, his publications rewarded him with numerous prizes and grants.